Taking a Light Approach to Treating Acute Ischemic Stroke Patients: Transcranial Near-infrared Laser Therapy Translational Science

Overview

Journal Ann Med

Publisher Informa Healthcare

Specialty General Medicine

Date 2010 Nov 3

PMID 21039081

Citations 31

Authors

Paul A Lapchak

Affiliations

Soon will be listed here.

Abstract

Transcranial near-infrared laser therapy (NILT) has been investigated as a novel neuroprotective treatment for acute ischemic stroke (AIS), for approximately 10 years. Two clinical trials, NeuroThera Effectiveness and Safety Trial (NEST)-1 and NEST-2, have evaluated the use of NILT to promote clinical recovery in patients with AIS. This review covers preclinical, translational, and clinical studies documented during the period 1997-2010. The primary aim of this article is to detail the development profile of NILT to treat AIS. Secondly, insight into possible mechanisms involved in light therapy will be presented. Lastly, possible new directions that should be considered to improve the efficacy profile of NILT in AIS patients will be discussed. The use of NILT was advanced to clinical trials based upon extensive translational research using multiple species. NILT, which may promote functional and behavioral recovery via a mitochondrial mechanism and by enhancing cerebral blood flow, may eventually be established as an Food and Drug Administration (FDA)-approved treatment for stroke. The NEST-3 trial, which is the pivotal trial for FDA approval, should incorporate hypotheses derived from translational studies to ensure efficacy in patients. Future NILT studies should consider administration of a thrombolytic to enhance cerebral reperfusion alongside NILT neuroprotection.

Citing Articles

Can infrared light really be doing what we claim it is doing? Infrared light penetration principles, practices, and limitations.

Henderson T Front Neurol. 2024; 15:1398894.

PMID: 39263274 PMC: 11388112. DOI: 10.3389/fneur.2024.1398894.

Photobiomodulation Therapy on Brain: Pioneering an Innovative Approach to Revolutionize Cognitive Dynamics.

Nairuz T, Sangwoo-Cho , Lee J Cells. 2024; 13(11.

PMID: 38891098 PMC: 11171912. DOI: 10.3390/cells13110966.

Chinese Stroke Association guidelines for clinical management of ischaemic cerebrovascular diseases: executive summary and 2023 update.

Liu L, Li Z, Zhou H, Duan W, Huo X, Xu W Stroke Vasc Neurol. 2023; 8(6):e3.

PMID: 38158224 PMC: 10800268. DOI: 10.1136/svn-2023-002998.

Revisiting Transcranial Light Stimulation as a Stroke Therapeutic-Hurdles and Opportunities.

Feng W, Domeracki A, Park C, Shah S, Chhatbar P, Pawar S Transl Stroke Res. 2022; 14(6):854-862.

PMID: 36369294 DOI: 10.1007/s12975-022-01103-7.

Photobiomodulation Improves Serum Cytokine Response in Mild to Moderate COVID-19: The First Randomized, Double-Blind, Placebo Controlled, Pilot Study.

Marashian S, Hashemian M, Pourabdollah M, Nasseri M, Mahmoudian S, Reinhart F Front Immunol. 2022; 13:929837.

PMID: 35874678 PMC: 9304695. DOI: 10.3389/fimmu.2022.929837.

References

Lapchak P . Development of thrombolytic therapy for stroke: a perspective. Expert Opin Investig Drugs. 2002; 11(11):1623-32. DOI: 10.1517/13543784.11.11.1623. View

Lyden P, Zivin J, Soll M, Sitzer M, Rothrock J, Alksne J . Intracerebral hemorrhage after experimental embolic infarction. Anticoagulation. Arch Neurol. 1987; 44(8):848-50. DOI: 10.1001/archneur.1987.00520200052018. View

Grotta J, Burgin W, El-Mitwalli A, Long M, Campbell M, Morgenstern L . Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000. Arch Neurol. 2001; 58(12):2009-13. DOI: 10.1001/archneur.58.12.2009. View

Shuaib A, Lees K, Lyden P, Grotta J, Davalos A, Davis S . NXY-059 for the treatment of acute ischemic stroke. N Engl J Med. 2007; 357(6):562-71. DOI: 10.1056/NEJMoa070240. View

Lapchak P, Salgado K, Chao C, Zivin J . Transcranial near-infrared light therapy improves motor function following embolic strokes in rabbits: an extended therapeutic window study using continuous and pulse frequency delivery modes. Neuroscience. 2007; 148(4):907-14. DOI: 10.1016/j.neuroscience.2007.07.002. View

. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995; 333(24):1581-7. DOI: 10.1056/NEJM199512143332401. View

WAUD D . On biological assays involving quantal responses. J Pharmacol Exp Ther. 1972; 183(3):577-607. View

Lapchak P, Araujo D, Zivin J . Comparison of Tenecteplase with Alteplase on clinical rating scores following small clot embolic strokes in rabbits. Exp Neurol. 2003; 185(1):154-9. DOI: 10.1016/j.expneurol.2003.09.009. View

Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R . Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995; 274(13):1017-25. View

10.

Lapchak P, Han M, Salgado K, Streeter J, Zivin J . Safety profile of transcranial near-infrared laser therapy administered in combination with thrombolytic therapy to embolized rabbits. Stroke. 2008; 39(11):3073-8. DOI: 10.1161/STROKEAHA.108.516393. View

11.

Ehrenreich H, Weissenborn K, Prange H, Schneider D, Weimar C, Wartenberg K . Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke. 2009; 40(12):e647-56. DOI: 10.1161/STROKEAHA.109.564872. View

12.

Lapchak P, Chapman D, Zivin J . Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke. 2000; 31(12):3034-40. DOI: 10.1161/01.str.31.12.3034. View

13.

Bluhmki E, Chamorro A, Davalos A, Machnig T, Sauce C, Wahlgren N . Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial. Lancet Neurol. 2009; 8(12):1095-102. DOI: 10.1016/S1474-4422(09)70264-9. View

14.

Ilic S, Leichliter S, Streeter J, Oron A, DeTaboada L, Oron U . Effects of power densities, continuous and pulse frequencies, and number of sessions of low-level laser therapy on intact rat brain. Photomed Laser Surg. 2006; 24(4):458-66. DOI: 10.1089/pho.2006.24.458. View

15.

Lynnerup N, Astrup J, Sejrsen B . Thickness of the human cranial diploe in relation to age, sex and general body build. Head Face Med. 2005; 1:13. PMC: 1351187. DOI: 10.1186/1746-160X-1-13. View

16.

Lapchak P . A new embolus injection method to evaluate intracerebral hemorrhage in New Zealand white rabbits. Brain Res. 2010; 1349:129-36. PMC: 2914803. DOI: 10.1016/j.brainres.2010.06.033. View

17.

Ferguson K, Kidwell C, Starkman S, Saver J . Hyperacute treatment initiation in neuroprotective agent stroke trials. J Stroke Cerebrovasc Dis. 2007; 13(3):109-12. DOI: 10.1016/j.jstrokecerebrovasdis.2004.04.001. View

18.

Liang H, Whelan H, Eells J, Wong-Riley M . Near-infrared light via light-emitting diode treatment is therapeutic against rotenone- and 1-methyl-4-phenylpyridinium ion-induced neurotoxicity. Neuroscience. 2008; 153(4):963-74. PMC: 2587428. DOI: 10.1016/j.neuroscience.2008.03.042. View

19.

Albers G, Bates V, Clark W, Bell R, Verro P, Hamilton S . Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA. 2000; 283(9):1145-50. DOI: 10.1001/jama.283.9.1145. View

20.

Uozumi Y, Nawashiro H, Sato S, Kawauchi S, Shima K, Kikuchi M . Targeted increase in cerebral blood flow by transcranial near-infrared laser irradiation. Lasers Surg Med. 2010; 42(6):566-76. DOI: 10.1002/lsm.20938. View